MedTrace Logo

Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain

NCT00452777 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 193

Last updated 2014-11-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and tolerability of BVT.115959 in diabetic patients with neuropathic pain who are either not on analgesia or are on stable analgesia in the month prior to entering the study.

Conditions

  • Diabetic Neuropathic Pain

Interventions

DRUG

BVT.115959

DRUG

Placebo

Sponsors & Collaborators

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Keith Bragman, MD FRCP FRCPath FFPM · Swedish Orphan Biovitrum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2007-12-31
Completion
2008-01-31

Countries

  • Czechia
  • Germany
  • South Africa

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00452777 on ClinicalTrials.gov